Francesco Di Marco Takes the Helm as CEO of Italfarmaco
Italfarmaco S.p.A. has officially announced the appointment of Dr. Francesco Di Marco as its new Chief Executive Officer (CEO), a significant move that will take effect from January 1, 2026. With over 25 years of extensive experience in the biopharmaceutical sector, Dr. Di Marco's leadership promises to continue the company’s innovative path, particularly in underserved therapeutic areas.
Qualifications of Dr. Francesco Di Marco
Dr. Francesco Di Marco has an impressive background, marked by senior roles in various prominent companies across Europe, the U.S., and emerging markets. His expertise spans global commercialization and strategy implementation, making him a valuable asset to Italfarmaco. His success in Oncology, Cardiovascular, Metabolic, and Rare Disease sectors provides a solid foundation for his new role.
A Commitment to Innovation
With a strong focus on R&D, Italfarmaco has created a diverse product lineup that focuses on critical areas such as haematology, oncology, cardiology, and women’s health. During his first remarks as CEO, Dr. Di Marco expressed his admiration for the company’s dedication to innovation, specifically highlighting the company’s treatment for Duchenne muscular dystrophy, givinostat (Duvyzat), which aims to bring transformative care to patients across the globe.
Embracing a New Era
Francesco De Santis, the Chairman of Italfarmaco Group, praised Dr. Di Marco's international vision, stating that his leadership is crucial as the company embarks on a new chapter defined by growth and strategic market expansion. This transition underscores Italfarmaco’s commitment to driving advancements in healthcare while ensuring the well-being of patients globally.
Italfarmaco’s Legacy and Future Direction
Founded in 1938, Italfarmaco has built a reputable journey of innovation and global expansion over the last eight decades. The company's achievements in pharmaceutical research and drug development have positioned it as a leader in various therapeutic fields including immuno-oncology and neurology. Their efforts in addressing Rare Diseases have been particularly commendable, highlighted through initiatives in conditions like Duchenne muscular dystrophy, which is critical to their mission.
Global Presence
Boasting a presence in over 90 countries, Italfarmaco operates through both direct entities and partnerships, ensuring efficient outreach and support for healthcare advancements. Their focus remains on developing high-quality health solutions that not only meet market needs but also significantly improve patient lives.
Ongoing Engagement with Stakeholders
In his new role, Dr. Di Marco is poised to engage with the leadership team, and Board members, and to foster relationships within the patient community. Continued collaboration with various partners will be essential to furthering Italfarmaco’s mission of delivering impactful healthcare solutions. This strategic alignment aims to enhance the legacy of the company while opening new avenues for therapeutic solutions in critical health areas.
Frequently Asked Questions
Who is the new CEO of Italfarmaco?
The new CEO of Italfarmaco is Dr. Francesco Di Marco, effective January 1, 2026.
What experience does Francesco Di Marco bring to Italfarmaco?
Francesco Di Marco has over 25 years of experience in the biopharmaceutical industry, with roles in various strategic positions across the globe.
What are the key therapeutic areas Italfarmaco focuses on?
Italfarmaco specializes in haematology, oncology, cardiology, immunology, and rare diseases, among others.
How many countries does Italfarmaco operate in?
Italfarmaco has operations in more than 90 countries worldwide.
What innovative treatment did Dr. Di Marco highlight during his announcement?
Dr. Di Marco highlighted the company's commitment to providing givinostat (Duvyzat) for Duchenne muscular dystrophy patients, showcasing their dedication to innovation.
